Absci Corporation (NASDAQ:ABSI) is one of the best multibagger penny stocks to buy right now. On December 12, Needham’s Gil Blum reiterated a Buy rating on Absci Corporation (NASDAQ:ABSI) with a $7 price target, citing encouraging preclinical data for ABS‑201 in androgenetic alopecia and strong market interest ahead of the planned HEADLINE study. Earlier, on December 4, JonesTrading also maintained a Buy rating with a $9 target. Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatmen ...

Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company focused on developing therapeutics using generative AI, participating in the 44th Annual J.P. Morgan Healthcare Conference to showcase its drug discovery advancements [1] Stock Performance - H.C. Wainwright set a price target of $8 for ABSI, indicating a potential increase of about 67.77% from its then-current price of $3.44; the stock is currently priced at $3.39, reflecting a slight decrease of 4.38% [2] - ABSI's stock has shown volatility, with a daily trading range between $3.38 and $3.64; over the past year, it reached a high of $6.33 and a low of $2.01, typical for clinical-stage biopharmaceutical companies [3] Market Position - Absci's market capitalization is approximately $510.4 million, indicating the total market value of its outstanding shares; the trading volume on NASDAQ is 1,986,998 shares, reflecting investor interest [4] - The company's innovative approach in drug discovery, combining AI and synthetic biology, positions it as a notable player in the biopharmaceutical industry [4]

Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company focused on drug discovery using generative AI and synthetic biology [1][5] - The company is participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating its commitment to innovation in therapeutics [4][5] Stock Performance - H.C. Wainwright maintains a "Buy" rating for Absci, raising the price target from $7 to $8, with the stock currently trading at $3.53 [2][5] - The stock has fluctuated between $3.50 and $3.64 during the day, with a yearly high of $6.33 and a low of $2.01 [3][5] - Absci's market capitalization is approximately $531.3 million, with a trading volume of 1,367,859 shares today, indicating active investor interest [3]

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Wednesday, January 14th at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time). Interested parties may access a live and archived webcast of ...

PresentationSean McClainFounder, CEO, President & Director Good morning, everyone. Thank you for joining our deep dive today into ABS-201. At Absci, our mission is to use generative AI to create better biologics for patients who don't have good enough options today. We talk a lot about our platform, our lab-in-the-loop, and our ability to create better biologics faster. But today isn't just about the platform in the abstract, today is about the results. ABS-201, which we believe could be a paradigm-changing ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of ABS-201 Conference Call Company and Industry Overview - **Company**: Absci - **Industry**: Biopharmaceuticals, specifically focusing on treatments for androgenetic alopecia (AGA) Key Points and Arguments 1. **Mission and Focus**: Absci aims to leverage generative AI to develop better biologics for patients with unmet medical needs, particularly in the area of hair loss, which is often dismissed as cosmetic but has significant psychosocial impacts on patients [1][2][13] 2. **ABS-201 Overview**: ABS-201 is positioned as a potentially paradigm-changing therapeutic for AGA, utilizing a novel mechanism involving the prolactin receptor pathway, which is believed to offer a differentiated and best-in-class profile [2][3][18] 3. **Patient Impact**: The psychosocial effects of hair loss are emphasized, with testimonials highlighting the emotional toll and identity issues faced by individuals suffering from AGA [5][7][12][13] 4. **Clinical Trial Design**: The upcoming phase 1/2a clinical trial for ABS-201 will assess safety, tolerability, and efficacy, with an interim efficacy readout expected in the second half of 2026 [43][45] 5. **Scientific Validation**: The mechanism of action for ABS-201 involves blocking the prolactin receptor, which has shown promising results in preclinical studies, including significant hair growth and repigmentation in non-human primates [22][23][40] 6. **Market Opportunity**: There is a significant commercial opportunity in the hair loss treatment market, especially as awareness and demand for effective treatments grow among both men and women [2][15][17][26] Additional Important Content 1. **Expert Insights**: Various experts, including dermatologists and researchers, provided insights into the biological mechanisms of hair loss and the potential of ABS-201 to address these issues [19][29][50] 2. **Historical Context**: The discussion included a historical perspective on hair loss treatments and the evolution of understanding regarding the role of hormones like prolactin in hair growth [30][51] 3. **Regulatory Considerations**: The trial design includes rigorous endpoints and assessments to ensure that the results are meaningful and can support regulatory approval [44][56] 4. **Patient-Centric Approach**: Emphasis on the importance of patient-reported outcomes alongside clinical measurements to gauge the true impact of treatment on quality of life [44][45] This summary encapsulates the critical aspects of the ABS-201 conference call, highlighting the innovative approach of Absci in addressing a significant medical need through advanced biopharmaceutical development.

GENERATIVE AI DRUG CREATION ABS-201 KOL SEMINAR ABSCI CORPORATION 2025 ALL RIGHTS RESERVED Disclaimers Forward-Looking Statements Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "anticipates," "plans," "believes," "forecast," "estimates," "expects," "predic ...

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today’s ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER, Wash. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWI ...

Core Insights - Absci Corporation has partnered with U.S. soccer legend Landon Donovan to address the emotional impact of androgenetic alopecia (AGA) and promote the need for innovative therapeutic options [1][3] - Donovan will share his personal experiences with hair loss during Absci's upcoming Key Opinion Leader seminar, emphasizing the importance of patient-driven insights in the development of the investigational antibody ABS-201 [2][3] Company Overview - Absci Corporation is a clinical-stage biopharmaceutical company focused on advancing therapeutics using generative AI, with a commitment to improving patient lives through innovative drug development [1][6] - The company is headquartered in Vancouver, WA, and has an AI Research Lab in New York City, along with an Innovation Center in Switzerland [6] Product Development - ABS-201 is a novel therapeutic targeting prolactin receptors to stimulate hair follicle regeneration, showing statistically significant superior hair regrowth compared to minoxidil in preclinical studies [5] - The company anticipates interim data from its Phase 1/2a HEADLINE study in the second half of 2026, which will provide further insights into the clinical development path and market opportunity for ABS-201 [5] Market Context - Androgenetic alopecia affects approximately 80 million Americans, with current FDA-approved treatments like minoxidil and finasteride offering limited efficacy and notable side effects [4] - The partnership with Donovan aims to destigmatize AGA and highlight the need for better treatment options, reinforcing Absci's commitment to addressing significant unmet medical needs in this area [1][3]